Redx Pharma Email Format
Pharmaceutical ManufacturingEngland, United Kingdom11-50 Employees
Redx Pharma is a clinical-stage biotechnology company focused on discovering and developing novel small-molecule therapeutics for cancer and fibrotic diseases. The company operates from Alderley Park in Cheshire, England, a site described as the UK’s largest single-site life science campus, where its team brings together medicinal chemistry, biology and clinical development expertise. Its portfolio includes RXC007, a ROCK2 inhibitor studied for idiopathic pulmonary fibrosis that progressed to Phase 2 in 2022, RXC008, a GI-targeted ROCK inhibitor for fibrostenotic Crohn's disease that began Phase 1 in 2024, and RXC004, a Porcupine inhibitor in oncology that entered Phase 2 in 2021. Redx relies on translational science and medicinal chemistry to advance compounds against validated targets. A recent development is the launch of the RXC008 Phase I trial in early 2024.